Literature DB >> 33818675

Alterations in retinal and choroidal thickness following nonarteritic anterior ischemic optic neuropathy.

Selen Akbulut1, Gökhan Pekel2, Evre Pekel3, Ebru Nevin Cetin4.   

Abstract

PURPOSE: To show alterations of retinal arteriolar caliber (RAC), retinal venular caliber (RVC), retinal nerve fiber layer thickness (RNFLT), peripapillary choroidal thickness (ppCT), and central macular thickness (CMT) in acute and chronic phases of nonarteritic anterior ischemic optic neuropathy (NAION).
METHODS: Forty-one eyes of 41 patients with NAION were included in this retrospective study. RAC, RVC, RNFLT, ppCT, and CMT measurements were performed via spectral-domain optical coherence tomography in the acute and chronic phases of NAION.
RESULTS: RVC, RNFLT, ppCT, and CMT were significantly thinner in the chronic phase compared to the acute phase (p < 0.001), whereas RAC remained similar throughout the visits (p = 0.26). The visual acuity difference between the acute and chronic phases was not correlated with the changes of RAC, RVC, RNFLT, ppCT, or CMT.
CONCLUSIONS: RVC, RNFLT, ppCT, and CMT decreases in the chronic phase when compared to the acute phase of NAION, whereas RAC does not change significantly.

Entities:  

Keywords:  Choroidal thickness; Ischemic optic neuropathy; Macular thickness; Retinal nerve fiber layer; Retinal vascular caliber

Year:  2021        PMID: 33818675     DOI: 10.1007/s10792-021-01829-7

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  1 in total

Review 1.  Choroidal Thickness in Acute Non-arteritic Anterior Ischemic Optic Neuropathy.

Authors:  Homayoun Nikkhah; Mohadeseh Feizi; Naser Abedi; Saeed Karimi; Mehdi Yaseri; Hamed Esfandiari
Journal:  J Ophthalmic Vis Res       Date:  2020-02-02
  1 in total
  1 in total

1.  A Potential Role of Acute Choroidal Expansion in Nonarteritic Anterior Ischemic Optic Neuropathy.

Authors:  Andrew J Feola; Christopher A Girkin; C Ross Ethier; Brian C Samuels
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-04-01       Impact factor: 4.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.